- Home
- PRFX vs DRMA Comparison
PRFX vs DRMA Comparison
Compare PRFX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- DRMA
- Stock Information
- Founded
- PRFX 2007
- DRMA 2014
- Country
- PRFX Israel
- DRMA United States
- Employees
- PRFX N/A
- DRMA N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- DRMA Health Care
- Exchange
- PRFX Nasdaq
- DRMA Nasdaq
- Market Cap
- PRFX 2.8M
- DRMA 3.3M
- IPO Year
- PRFX 2020
- DRMA 2021
- Fundamental
- Price
- PRFX $1.25
- DRMA $3.97
- Analyst Decision
- PRFX Hold
- DRMA Strong Buy
- Analyst Count
- PRFX 1
- DRMA 1
- Target Price
- PRFX N/A
- DRMA $10.00
- AVG Volume (30 Days)
- PRFX 187.7K
- DRMA 344.3K
- Earning Date
- PRFX 11-14-2025
- DRMA 11-12-2025
- Dividend Yield
- PRFX N/A
- DRMA N/A
- EPS Growth
- PRFX N/A
- DRMA N/A
- EPS
- PRFX N/A
- DRMA N/A
- Revenue
- PRFX N/A
- DRMA N/A
- Revenue This Year
- PRFX N/A
- DRMA N/A
- Revenue Next Year
- PRFX N/A
- DRMA N/A
- P/E Ratio
- PRFX N/A
- DRMA N/A
- Revenue Growth
- PRFX N/A
- DRMA N/A
- 52 Week Low
- PRFX $1.20
- DRMA $3.83
- 52 Week High
- PRFX $16.63
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- PRFX 41.76
- DRMA 38.17
- Support Level
- PRFX $1.22
- DRMA $3.83
- Resistance Level
- PRFX $1.37
- DRMA $4.44
- Average True Range (ATR)
- PRFX 0.09
- DRMA 0.41
- MACD
- PRFX -0.01
- DRMA -0.09
- Stochastic Oscillator
- PRFX 7.15
- DRMA 6.86
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.